Fig. 5: PALOMA-2–specific associations point to a potentially stronger role of the T-cell–inflamed TME in mediating palbociclib resistance in the front-line setting.
From: Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
a Gene expression/PFS association result (numeric value and color intensity represent statistical significance of the association; red = resistance, green = sensitivity) of enriched interferon-gamma response and PD1 signaling genes from palbociclib plus ET treatment in PALOMA-2, PALOMA-3, and the postmenopausal patient/metastatic sample subset of PALOMA-3, respectively. b Relationship of PFS and the expression of a T-cell–inflamed TME signature that has been shown to be a pan-tumor predictive biomarker for immune checkpoint inhibitor response in the clinic23 in PALOMA-2 (top panel) and PALOMA-3 (bottom panel) cohorts from median (left panel) and quartile (right panel) analyses. c Association between PFS and the expression of various immune cell types from palbociclib plus ET treatment. Shown is statistical significance in the direction of resistance (top) or sensitivity (bottom); blue lines mark P-value of 0.05. ET endocrine therapy; MDSC myeloid-derived suppressor cell; Mets metastatic; PFS progression-free survival; TME tumor microenvironment.
